Abstract: This invention provides REL inhibitors which interfere with the DNA binding capacity of a REL protein. Additionally this invention provides methods of treating, abrogating, or preventing diseases which respond with a positive clinical score to a REL inhibitor. Methods of identifying REL inhibitor based on a REL protein three dimensional model are described.

Abstract: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

Abstract: The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC50 values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non-small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.

Abstract: Anti-cancer compositions and methods are described including one or more isothiocyanates and/or isoselenocyanates. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation.

Abstract: Carbamimidothioic acid esters of formula (I) and 2-nitro-N-[4-(pyridin-4-ylamino)phenyl]-4-(quinolin-4-ylamino)benzamide are used for the treatment of influenza, and for the inhibition of a viral RNA-dependent RNA polymerase. Formulae (I), (II).

Abstract: A composite particle comprises i) an hydrophobic particle that adheres to the cuticle of one or more species of animal infesting arthropod; and ii) at least one organic chemical compound admixed therewith, wherein the said organic chemical is capable of controlling the population of at least one animal infesting arthropod species. Experiments proved the efficacy of the particle, for example in powder form, in relation to a variety of arthropods, for example red poultry mites.

Abstract: Described herein is the use of ribonucleotide reductase inhibitors in the prevention or treatment of restenosis and other vascular proliferative disorders.

Abstract: There is provided a compound having an excellent controlling effect on pests, represented by the formula (I): wherein, A and E independently represent a —R1 group, a -L1-R1 group, etc.; G represents a -L2-R1 group, a —S(O)2—R4 group, etc.; X represents a —S—R5 group or a —O—R6 group; Z represents an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; R1 represents an optionally substituted C1-C20 chain hydrocarbon group, etc.; R5 represents a substituted C1-C4 alkyl group, an optionally substituted C5-C10 alkyl group, etc.; R6 represents a substituted C1-C2 alkyl group, an optionally substituted C3-C10 alkyl group, etc.; L1 represents a an oxygen atom, a sulfur atom, a —S(O)— group, or a —S(O)2— group; and L2 represents an oxygen atom or a sulfur atom.

Abstract: The present invention provides, for example, a compound of the following formula (I): wherein R1 is substituted amino and the like, R2 is halogen and the like, R3 is substituted or unsubstituted lower alkyl and the like, RA and RB are each independently hydrogen, substituted or unsubstituted lower alkyl and the like, RC and RD are each independently hydrogen, substituted or unsubstituted lower alkyl, or RC and RD together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle, and ring A is a carbocycle or a heterocycle, its pharmaceutically acceptable salt, or a solvate thereof as a therapeutic agent for diseases induced by production, secretion and/or deposition of amyloid-?proteins.

Abstract: The compound (I) or a salt thereof has an excellent controlling activity against pests. Then the compound (I) or a salt thereof is useful for an active ingredient of a pesticidal composition.

Abstract: The identification of MreB as essential for bacterial chromosome segregation provides a new target for antibiotic action. The MreB function is useful in the development of screening assays for new antibiotics, which may use, for example, genetic mutants in MreB, tests of MreB mediated chromosome segregation, and the like. In one embodiment of the invention, the antibiotic is an isothiourea compound, which may comprise a polyhalogenated benzyl group, e.g. at the 4 position, the 2,4 position, etc. A pharmaceutical composition comprising an MreB targeted antibiotic as an active agent is administered to a patient suffering from a microbial infection, particularly bacterial infections.

Abstract: There is provided a compound having an excellent controlling effect on pests, represented by the formula (I): wherein, A and E independently represent a —R1 group, a -L1-R1 group, etc.; G represents a -L2-R1 group, a —S(O)2—R4 group, etc.; X represents a —S—R5 group or a —O—R6 group; Z represents an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; R1 represents an optionally substituted C1-C20 chain hydrocarbon group, etc.; R5 represents a substituted C1-C4 alkyl group, an optionally substituted C5-C10 alkyl group, etc.; R6 represents a substituted C1-C2 alkyl group, an optionally substituted C3-C10 alkyl group, etc.; L1 represents a an oxygen atom, a sulfur atom, a —S(O)— group, or a —S(O)2-group; and L2 represents an oxygen atom or a sulfur atom.

Abstract: Microbicidal compositions including (a) cyanodithiocarbimate and (b) an N-alkyl heterocyclic compound; a triazole compound or salt thereof or metal complex thereof; a microbicide with an activated halogen atom or a formaldehyde releasing compound; 1,4-bis(bromoacetoxy)-2-butene; 2-(thiocyanomethylthio)benzothiazole; a methylene-bis(thiocyanate); a halogenated acetophenone; a halopropynl compound; an iodosulfone; a phenol; a halocyanoacetamide compound and/or a quaternary ammonium compound are described. Components (a) and (b) can be present in a synergistically effective amount to control the growth of at least one microorganism. Methods for controlling the growth of microorganisms with the compositions are also disclosed.

Abstract: Compounds of formula (I) and (II) are provided as modulators of Rb:Raf-1 interactions which are potent, selective disruptors of Rb:Raf-1 binding. Therapeutic methods of using the compounds, for example for treating or ameliorating a cell proliferation disorder such as cancer, are provided.

Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.

Abstract: A patient with a disease associated with a receptor having a cysteine residue is treated with a thiol reactive agent. The diseases include neurodegenerative diseases. Diseases characterized by skeletal muscle atrophy are also treated.

Abstract: The present invention relates to soil-applied CR granules obtainable by applying an active-ingredient-comprising coating to a solid carrier in a fluidized bed, to a process for the preparation of these soil-applied granules, and to a method for controlling phytopathogenic fungi, undesired vegetation, undesired attack by insects and/or for regulating the growth of plants using the soil-applied CR granules according to the invention.

Abstract: The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment of the disclosure relates to compounds of Formula (I); or an isomer, a pharmaceutically acceptable salt or solvate thereof or a pharmaceutically acceptable formulation comprising said compounds are useful for the useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.

Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.

Abstract: The present invention relates to an antiandrogen compound and a method of treating prostate cancer in a patient utilizing the compound. The present invention also relates to a pharmaceutical composition which includes the compound.

Abstract: Benzene-sulphonamide derivatives complying with the general formula (I): in which the different symbols have different meanings, their optical isomers and the salts pharmacologically acceptable of these derivatives, as well as their uses for drug manufacture and as radiolabelled pharmacological tools of the thromboxan A2 receptors.

Abstract: The present invention relates to novel N,N,-Substituted S-Aryl-Isothioureas, and N,N,N′-Substituted S-Aryl-Isothioureas and combinatorial libraries thereof, as well as methods of preparing N,N,-Substituted S-Aryl-Isothioureas, and N,N,N′-Substituted S-Aryl-Isothiourea derivative compounds.

Abstract: The invention provides fungicidal compounds of formula I and salts thereof: wherein the various radicals and substituents are as defined in the description, fungicidal compositions containing them and method for combating fungi which comprises applying these.

Abstract: Compounds of the formula are provided wherein R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, C1-C8 alkyl, C1-C6 alkoxy, nitro, cyano, acetoxy, amino, carboxy, sulfamyl, lower acylsulfamyl and trifluoromethyl. The compounds are inhibitors of cyclooxygenase-2 activity, useful for treating inflammation and cyclooxygenase-mediated disorders.

Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively; an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxyl amine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.

Abstract: The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent.

Abstract: The present invention relates to cosmetic compositions that comprise: a) a safe and effective amount of a 1,2-heteroatom constituted diene bonding agent having the structure: wherein X represents a cosmetic benefit agent that may or may not be attached to a chemical linker, Y represents N, CH, or CW wherein W is an alkyl and R represents O, S, or Se; and b) a cosmetically acceptable carrier for the bonding agent wherein the composition is administered topically to mammalian proteinaceous substrates and wherein the bonding agent reacts with a protein contained in the substrate such that the bonding agent, and thus the cosmetic benefit agent, is covalently attached to the substrate. The invention further relates to methods of using the compositions described above as well as various products that include the claimed compositions.

Abstract: The present invention relates to an antiandrogen compound and a method of treating prostate cancer in a patient utilizing the compound. The present invention also relates to a pharmaceutical composition which includes the compound.

Abstract: The invention refers to pharmaceutical compositions having an enhanced antiviral activity and/or decreased side effects. The composition comprises a hydroximic acid derivative of formula (I), or a therapeutically useful acid addition salt thereof and a known antiviral agent or, if desired, a therapeutically useful acid addition or therapeutically useful salt thereof.

Abstract: An apoptosis inducing agent or an anticancer agent which is characterized in containing glycerolipid and/or glyceroglycolipid as effective component(s).

Abstract: The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerebral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.

Abstract: The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerbral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.

Abstract: The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerebral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.

Abstract: A process for producing benzamidoximes represented by general formula (II), which are useful as intermediates of pesticides and drugs, at a stable and high yield by reacting benzonitriles represented by general formula (I) with hydroxylamine in the presence of a chelating agent wherein X represents halogeno, C1-5alkyl, C1-3 alkoxy, C1-3 alkylthio, hydroxy, mercapto, amino, nitro or C1-5haloalkyl; and n is 0 or an integer of from 1 to 5.

Abstract: A fungicidal mixture comprising a) an oxime ether of the formula I where the substituents have the following meanings: X is oxygen or amino (NH); Y is CH or N; Z is oxygen, sulfur, amino (NH) or C1-C4-alkylamino (N-alkyl); R′ is alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkylmethyl, or, if desired, substituted benzyl; a) an oxime ether of the formula I where the substituents have the following meanings: X is oxygen or amino (NH); Y is CH or N; Z is oxygen, sulfur, amino (NH) or C1-C4-alkylamino (N—C1-C4-alkyl); R′ is C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-alkenyl, C2-C6-haloalkenyl, C3-C6-alkynyl, C3-C6-haloalkynyl, C3-C6-cycloalkylmethyl, or is benzyl which can be partially or fully halogenated and/or can have attached to it one to three of the following radicals: cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy and C1-C4-alkylthio; and at least one compound from groups b)-c): b.

Abstract: A composition comprising effective amounts of a) a carbamate of the formula I where T is CH or N, n is 0, 1 or 2 and R is halogen, C1-C4-alkyl or C1-C4-haloalkyl, it being possible for the radicals R to be different if n is 2, and c) a compound III selected from the group consisting of the oxime ether carboxylate IIIa, the oxime ether carboxamide IIIb and the methoxyacrylate IIIc and optionally an oxime ether (II) and/or an azole (IV) as defined in the specification which exhibits a synergistically enhanced fungicidal effect is described.

Abstract: S-Alkylisothiouronium salts with phosphorus-containing acids are described. The compounds are used in processes of treating acute hypotension, which may result, for example, from shock or hemorrhage, and in processes for treating hyperoxic conditions, for example, oxygen poisoning.

Abstract: Fungicidal mixtures, comprisinga) an oxime ether of the formula I ##STR1## where the substituents have the following meanings: X is oxygen or amino (NH);Y is CH or N;Z is oxygen, sulfur, amino (NH) or C.sub.1 -C.sub.4 -alkylamino (N--C.sub.1 -C.sub.4 -alkyl);R' is C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.3 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -haloalkenyl, C.sub.3 -C.sub.6 -alkynyl, C.sub.3 -C.sub.6 -haloalkynyl, C.sub.3 -C.sub.6 -Cycloalkylmethyl, or is benzyl which can be partially or fully halogenated and/or can have attached to it one to three of the following radicals: cyano, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -haloalkyl, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -haloalkoxy and C.sub.1 -C.sub.4 -alkylthio and/orb) a carbamate of the formula II ##STR2## where T is CH or N, n is 0, 1 or 2 and R is halogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.

Abstract: Fungicidal mixtures, comprisinga) an oxime ether of the formula I ##STR1## where the substituents have the following meanings: X is oxygen or amino (NH);Y is CH or N;Z is oxygen, sulfur, amino (NH) or C.sub.1 -C.sub.4 -alkylamino (N--C.sub.1 -C.sub.4 -alkyl);R' is C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.3 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -haloalkenyl, C.sub.3 -C.sub.6 -alkynyl, C.sub.3 -C.sub.6 -haloalkynyl, C.sub.3 -C.sub.6 -cycloalkylmethyl, or is benzyl which can be partially or fully halogenated and/or can have attached to it one to three of the following radicals: cyano, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -haloalkyl, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -haloalkoxy and C.sub.1 -C.sub.4 -alkylthio and/orb) a carbamate of the formula II ##STR2## where T is CH or N, n is 0, 1 or 2 and R is halogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.

Abstract: Fungicidal mixtures, comprising a) a carbamate of the formula I ##STR1## where T is CH or N, n is 0, 1 or 2 and R is halogen, C.sub.1 --C.sub.4 --alkyl or C.sub.1 --C.sub.4 --haloalkyl, it being possible for the radicals R to be different when n is 2, and/orb) an oxime ether of the formula II ##STR2## where X is oxygen or amino (NH);Y is CH or N;Z is oxygen, sulfur, amino (NH) or C.sub.1 --C.sub.4 --alkylamino (N--C.sub.1 --C.sub.4 --alkyl);R' is C.sub.1 --C.sub.6 --alkyl, C.sub.1 --C.sub.6 --haloalkyl, C.sub.3 --C.sub.6 --alkenyl, C.sub.2 --C.sub.6 --haloalkenyl, C.sub.3 --C.sub.6 --alkynyl, C.sub.3 --C.sub.6 --haloalkynyl, (C.sub.3 --C.sub.6 --cycloalkyl)methyl, or is benzyl which may be partially or fully halogenated and/or carry one to three of the following radicals: cyano, C.sub.1 --C.sub.4 --alkyl, C.sub.1 --C.sub.4 --haloalkyl, C.sub.1 --C.sub.4 --alkoxy, C.sub.1 --C.sub.4 --haloalkoxy and C.sub.1 --C.sub.

Abstract: The compounds of formula I ##STR1## wherein: a) X is O, andY is OC.sub.1 -C.sub.4 alkyl; orb) X is O or S, andY is NHCH.sub.3have fungicidal properties and can be used in plant protection for controlling and preventing disease infestation.

Abstract: The invention pertains to phenylcarbamates of formula (I), wherein X is a direct bond, O or NR.sup.a ; Z is O, S or NR.sup.b- ; R.sup.1 is hydrogen, alkyl or alkyl halide; R.sup.2 is substituted methyl or optionally substituted alkyl, alkenyl, alkinyl or cycloalkyl; R.sup.3 is optionally substituted alkyl, alkenyl or alkinyl; R.sup.4 is alkyl, alkenyl or alkinyl and, if X is NR.sup.a, hydrogen also; R.sup.5 is hydrogen or optionally substituted alkyl, alkenyl, alkinyl, alkyl carbonyl or alkoxy carbonyl. The invention also pertains to methods for their preparation and agents containing them.

Abstract: Fungicidal mixtures, comprisinga.sub.1) a carbamate of the formula I ##STR1## where T is CH or N, n is 0, 1 or 2 and R is halogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -haloalkyl, it being possible for the radicals R to be different when n is 2, and/ora.sub.2) an oxime ether of the formula II ##STR2## where the substituents have the following meaning: X is oxygen or amino (NH);Y is CH or N;Z is oxygen, sulfur, amino (NH) or C.sub.1 -C.sub.4 -alkylamino (N--C.sub.1 -C.sub.4 -alkyl);R' is C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.3 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -haloalkenyl, C.sub.3 -C.sub.6 -alkynyl, C.sub.3 -C.sub.6 -haloalkynyl, C.sub.3 -C.sub.6 -cycloalkyl-methyl, or benzyl which may be partially or fully halogenated and/or may carry one to three of the following radicals: cyano, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -haloalkyl, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -haloalkoxy and C.sub.1 -C.sub.

Abstract: Compounds represented by the general formula (I): ##STR1## (where R.sub.1 denotes a hydrogen atom, a straight-chained or branched alkoxycarbonyl group having 1-6 carbon atoms in which the alkyl portion may optionally have a substituent, or an optionally substituted straight-chained or branched acyl group having 1-9 carbon atoms;R.sub.2 denotes a hydrogen atom or an optionally substituted straight-chained or branched alkyl group having 1-6 carbon atoms;R.sub.3 denotes an optionally substituted straight-chained or branched alkyl group having 1-6 carbon atoms or an optionally substituted straight-chained or branched alkenyl group having 2-6 carbon atoms;R.sub.4 denotes a hydrogen atom;or alternatively R.sub.3 and R.sub.4 may combine together to form an optionally substituted 5- to 7-membered ring; andn denotes an integer of 2-4, provided that when R.sub.3 is a methyl group, n is not 3 at the same time) or pharmaceutically acceptable salts thereof.

Abstract: A fungicidal mixture comprisinga) an oxime ether of the formula I ##STR1## where the substituents have the following meaning: X is oxygen or amino (NH);Y is CH or N;Z is oxygen, sulfur, amino (NH) or C.sub.1 -C.sub.4 -alkylamino (N--C.sub.1 -C.sub.4 -alkyl);R' is C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.3 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -haloalkenyl, C.sub.3 -C.sub.6 -alkynyl, C.sub.3 -C.sub.6 -haloalkynyl, C.sub.3 -C.sub.6 -cycloalkylmethyl, or benzyl which may be partially or fully halogenated and/or may carry one to three of the following radicals: cyano, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -haloalkyl, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -haloalkoxy and C.sub.1 -C.sub.

Abstract: The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerebral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.

Abstract: Fungicidal mixtures, comprisinga) a carbamate of the formula I ##STR1## where T is CH or N, n is 0, 1 or 2 and R is halogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -haloalkyl, it being possible for the radicals R to be different when n is 2, and/orb) an oxime ether of the formula II ##STR2## where the substituents have the following meaning: X is oxygen or amino (NH);Y is CH or N;Z is oxygen, sulfur, amino (NH) or C.sub.1 -C.sub.4 -alkylamino (N--C.sub.1 -C.sub.4 -alkyl);R' is C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.3 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -haloalkenyl, C.sub.3 -C.sub.6 -alkynyl, C.sub.3 -C.sub.6 -haloalkynyl, C.sub.3 -C.sub.6 -cycloalkylmethyl, or is benzyl which can be partially or fully halogenated and/or have attached to it one to three of the following radicals: cyano, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -haloalkyl, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -haloalkoxy, and C.sub.1 -C.sub.

Abstract: The present invention relates to an antiandrogen compound and a method of treating prostate cancer in a patient utilizing the compound. The present invention also relates to a pharmaceutical composition which includes the compound.

Abstract: There is disclosed a microbicidal composition comprising as active ingredients:(I) a dithiocarbonimide compound represented by the general formula: ##STR1## wherein Z represents CH group or nitrogen atom, R.sup.1 and R.sup.2 are the same or different and represent hydrogen atom, C.sub.1 -C.sub.6 alkyl group, halogen atom, C.sub.1 -C.sub.6 alkoxy group, C.sub.1 -C.sub.6 haloalkyl group or C.sub.1 -C.sub.6 haloalkoxy group, or R.sup.1 and R.sup.2 are taken together to form methylenedioxy group optionally substituted with fluorine atom, and(II) at least one compound selected from the group consisting of ethylenebis (dithiocarbamate) compound, copper compound, phthalimide microbicidal compound, chlorothalonil, anilide microbicidal compound, cymoxanil, dimethomorph and fosetyl.

Abstract: 2-Iminooxyphenylacetic acid derivatives ##STR1## where the substituents and the index have the following meanings: R.sup.1 is C(CO.sub.2 CH.sub.3).dbd.NOCH.sub.3 (Ia), C(CONHCH.sub.3).dbd.NOCH.sub.3 (Ib), C(CONH.sub.2).dbd.NOCH.sub.3 (Ic), C(CO.sub.2 CH.sub.3).dbd.CHOCH.sub.3 (Id) or C(CO.sub.2 CH.sub.3).dbd.CHCH.sub.3 (Ie);R.sup.2 is cyano, nitro, halogen, alkyl, haloalkyl or alkoxy;m is 0, 1 or 2;R.sup.3 is hydrogen, cyano, hydroxyl, halogen,alkyl, haloalkyl, alkoxyalkyl, alkoxy, haloalkoxy, alkylthio, cyclopropyl, alkenyl,unsubstituted or substituted aryloxyalkyl, benzyl or benzyloxy,R.sup.4 is hydrogen, cyano,unsubstituted or substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and hetaryl;unsubstituted or substituted alkoxy, alkenyloxy, alkynyloxy, cycloalkoxy, heterocyclyloxy, aryloxy and hetaryloxy;unsubstituted or substituted arylthio and hetarylthio;--Q--C(R.sup.5).dbd.N--Y.sup.1 --R.sup.6 or --Q--O--N.dbd.CR.sup.7 R.sup.8,R.sup.3 and R.sup.